The influence of delivery vectors on HIV vaccine efficacy

Ondondo, Beatrice

doi:10.3389/fmicb.2014.00439

Cited by 27 publications

(21 citation statements)

References 300 publications

(383 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Other viral vector systems have been tested for their ability to induce HIV-specific B cell responses. [95][96][97] Replicationdeficient poxvirus-and adenovirus-based vaccines are perhaps the best studied viral vectors in the context of an HIV vaccine. Early immunogenicity studies of nonreplicating adenovirus expressing HIV-1 env in mice showed that a boost was required to induce anti-HIV-1 Env antibodies using higher titers of vaccine.…”

Section: Discussionmentioning

confidence: 99%

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses

Dunkel

Shen

LaBranche

et al. 2015

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

We previously showed that a matrix (M) gene-deleted rabies virus (RABV)-based vaccine (RABV-DM) is highly immunogenic and induces potent B cell responses in the context of RABV infection. We speculated that RABV-DM expressing HIV proteins would also induce potent B cell responses against HIV antigens. As a prerequisite to future studies in nonhuman primates, we completed immunogenicity studies in mice to confirm the ability of RABV-DM to induce polyfunctional B cell responses in the context of HIV. To that end, the envelope protein from the mac239 strain of SIV (SIVmac239Env) was cloned into RABV-DM, resulting in RABV-DM-Env. Infectious virus was recovered following standard methods and propagated on baby hamster kidney cells stably expressing RABV M [ > 10 7 focus forming units (ffu)/ml]. Western blot analysis of cell lysates or of purified virions confirmed Env expression on the surface of infected cells and within virus particles, respectively. Positive neutralization activity against a neutralization-sensitive SIV strain and to a lesser extent against a neutralization-resistant SIV strain was detected in mice after a single intramuscular inoculation with RABV-DM-Env. The quality, but not quantity, of the antibody response was enhanced via boosting with recombinant gp130 or RABV-DM-Env as measured by an increase in antibody avidity and a skewing toward a Th1-type antibody response. We also show that an intradermal inoculation induces higher antibodies than an intramuscular or intranasal inoculation. An intradermal inoculation of RABV-DM-Env followed by a boost inoculation with recombinant gp130 produced anti-SIV antibodies with neutralizing and nonneutralizing antibody (nNAb) effector functions. Together, RABV-DM-Env induces B cells to secrete antibodies against SIV with the potential to clear both ''free'' and cell-associated virus. Strategies capable of eliciting both NAbs as well as nNAbs might help to improve the efficacy of HIV-1 vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses

Dunkel

Shen

LaBranche

et al. 2015

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…In the recent past, highly attenuated poxviruses continued to play a major role in the international search for an AIDS vaccine also taking advantage of established technologies for vector vaccine production at industrial scale. Different recombinant MVAexpressing HIV proteins have undergone preclinical and clinical testing for the activation of protective immune responses against AIDS often in combination with DNA-based and/or adenoviral vector vaccines (for review, see Iyer and Amara, 2014;Ondondo, 2014). Recombinant MVA vaccines targeting different HIV-1 subtypes continued to prove safe and immunogenic in additional clinical studies (Goepfert et al, 2014;Joachim et al, 2015;Munseri et al, 2015;Nilsson et al, 2015).…”

Section: Vector Vaccines Against Aids Tuberculosis and Malariamentioning

confidence: 99%

Modified Vaccinia Virus Ankara

Volz

Sutter

2017

Advances in Virus Research

266

137

View full text Add to dashboard Cite

Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment. As a biologically well-characterized mutant virus, MVA facilitates fundamental research to elucidate the functions of poxvirus host-interaction factors. As extremely safe viral vectors MVA vaccines have been found immunogenic and protective in various preclinical infection models. Multiple recombinant MVA currently undergo clinical testing for vaccination against human immunodeficiency viruses, Mycobacterium tuberculosis or Plasmodium falciparum. The versatility of the MVA vector vaccine platform is readily demonstrated by the swift development of experimental vaccines for immunization against emerging infections such as the Middle East Respiratory Syndrome. Recent advances include promising results from the clinical testing of recombinant MVA-producing antigens of highly pathogenic avian influenza virus H5N1 or Ebola virus. This review summarizes our current knowledge about MVA as a unique strain of vaccinia virus, and discusses the prospects of exploiting this virus as research tool in poxvirus biology or as safe viral vector vaccine to challenge existing and future bottlenecks in vaccinology.

show abstract

“…Altenburg et al [48] Nébié et al [44] Arroyo et al [34] Nieto and Salvetti [30] Babu Appaiahgari and Vrati [33] Ondondo [52] Banchereau and Steinman [36] Pandey et al [27] Bermúdez-Humarán et al [58] Paris et al [43] Bråve et al [28] Ploquin et al [31] Chin'ombe et al [60] Rimmelzwaan and Sutter [55] Choi and Chang [35] Robertson [51] Cottingham et al [56] Rollier et al [11] Croyle et al [41] Saxena et al [39] Dicks et al [40] Smith Tatsis and Ertl [37] Ewer et al [45] Tripp and Tompkins [47] Gómez et al [49] Ulmer et al [3] Hessel et al [54] Ura et al [32] Kreijtz et al [26] Verheust et al [53] Lundstrom [46] Weaver and Barry [42] Mooney and Tompkins [38] Williams et al [29] Myhr et al [50] Youngjoo et al (2013) For the clinical trials analysis, a similar procedure was applied. Instead of searching for CPC codes, data on the technology class of the vaccine was extracted from the previously generated clinical trial database by searching the variable ''Expression System".…”

Section: Patents and Clinical Trialsmentioning

confidence: 99%

Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

Ramezanpour

Haan

Osterhaus

et al. 2016

Vaccine

View full text Add to dashboard Cite

The global vaccine market is diverse while facing a plethora of novel developments. Genetic modification (GM) techniques facilitate the design of 'smarter' vaccines. For many of the major infectious diseases of humans, like AIDS and malaria, but also for most human neoplastic disorders, still no vaccines are available. It may be speculated that novel GM technologies will significantly contribute to their development. While a promising number of studies is conducted on GM vaccines and GM vaccine technologies, the contribution of GM technology to newly introduced vaccines on the market is disappointingly limited. In this study, the field of vector-based GM vaccines is explored. Data on currently available, actually applied, and newly developed vectors is retrieved from various sources, synthesised and analysed, in order to provide an overview on the use of vector-based technology in the field of GM vaccine development. While still there are only two vector-based vaccines on the human vaccine market, there is ample activity in the fields of patenting, preclinical research, and different stages of clinical research. Results of this study revealed that vector-based vaccines comprise a significant part of all GM vaccines in the pipeline. This study further highlights that poxviruses and adenoviruses are among the most prominent vectors in GM vaccine development. After the approval of the first vectored human vaccine, based on a flavivirus vector, vaccine vector technology, especially based on poxviruses and adenoviruses, holds great promise for future vaccine development. It may lead to cheaper methods for the production of safe vaccines against diseases for which no or less perfect vaccines exist today, thus catering for an unmet medical need. After the introduction of Jenner's vaccinia virus as the first vaccine more than two centuries ago, which eventually led to the recent eradication of smallpox, this and other viruses may now be the basis for constructing vectors that may help us control other major scourges of mankind.

show abstract

The influence of delivery vectors on HIV vaccine efficacy

Cited by 27 publications

References 300 publications

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses

A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses

Modified Vaccinia Virus Ankara

Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

Contact Info

Product

Resources

About